Low-Dose Naltrexone (LDN)

Research-Grade

Low-Dose Naltrexone (LDN) refers to the use of naltrexone — an FDA-approved opioid receptor antagonist normally prescribed at 50 mg for addiction — at dramatically reduced doses of 0.5–4.5 mg, typically taken at bedtime. At these sub-therapeutic antagonist doses, naltrexone produces a brief, transient blockade of opioid receptors (primarily mu and delta) lasting approximately 4–6 hours. The body interprets this transient blockade as an endorphin deficit and compensates by upregulating the production of endogenous opioid peptides including beta-endorphin and met-enkephalin, as well as increasing opioid receptor density. This rebound effect, occurring after the drug clears, results in a net enhancement of the endogenous opioid system by the following morning. Additionally, LDN has been shown to antagonize Toll-like receptor 4 (TLR4) on microglia and macrophages, suppressing pro-inflammatory cytokine cascades (TNF-α, IL-6, NF-κB signaling) independently of its opioid receptor activity. The clinical interest in LDN spans a remarkable range of conditions characterized by immune dysregulation and chronic inflammation. The most robust evidence base exists for fibromyalgia, where two small randomized controlled trials (Younger et al., Stanford, 2013) demonstrated statistically significant reductions in pain severity compared to placebo, with approximately 30% of participants achieving a greater-than-30% reduction in symptoms. Multiple sclerosis has been another active area, with a pilot RCT (Cree et al., UCSF, 2010) showing improvements in quality of life measures. Case series and retrospective analyses have reported benefits in Crohn's disease, Hashimoto's thyroiditis, complex regional pain syndrome, and various other autoimmune conditions, though large-scale phase 3 trials remain absent. The LDN Research Trust and affiliated academic groups continue to compile observational data. LDN's safety profile is notably benign. The most commonly reported side effects are vivid dreams (consistent with increased endorphin activity during REM sleep) and transient sleep disruption during the first 1–2 weeks of use. Serious adverse events are exceedingly rare in the published literature. However, LDN is contraindicated in patients currently taking full-dose opioid medications, as even low-dose antagonism can precipitate acute withdrawal. The compound is not available as a commercial product at LDN doses; it must be obtained through compounding pharmacies that prepare the 0.5–4.5 mg capsules from standard 50 mg naltrexone tablets. This compounding requirement, combined with the lack of patent protection and pharmaceutical industry investment, has been a primary barrier to large-scale clinical trial execution.